

Financial news for RXII dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for RXII dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for RXII dated on 2018-11-14: RXi Pharma Reports Corporate Name Change To Phio Pharma, Ticker Will Change To 'PHIO'

Financial news for RXII dated on 2018-11-14: RXi Pharma Names Gerrit Dispersyn Pres, COO

Financial news for RXII dated on 2018-11-14: RXi Pharmaceuticals Q3 EPS \$(0.34) Beats \$(0.38) Estimate, Sales \$57K Beat \$50K Estimate

Financial news for RXII dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for RXII dated on 2018-11-11: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for RXII dated on 2018-11-07: RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018

Financial news for RXII dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for RXII dated on 2018-10-11: The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Financial news for RXII dated on 2018-10-10: RXi Pharma 13G From CVI Investments Shows New 9.9% Stake

Financial news for RXII dated on 2018-10-10: Stocks Which Set New 52-Week Low Yesterday, October 9th

Financial news for RXII dated on 2018-10-04: Stocks Which Set New 52-Week Low Yesterday, October 3rd

Financial news for RXII dated on 2018-10-03: Stocks Which Set New 52-Week Low Yesterday, October 2nd

Financial news for RXII dated on 2018-10-02: Stocks Which Set New 52-Week Low Yesterday, October 1st

Financial news for RXII dated on 2018-10-02: The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

Financial news for RXII dated on 2018-10-02: 48 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-10-01: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for RXII dated on 2018-10-01: RXi Pharmaceuticals shares are down 49.2% premarket after the company priced a 21.4 million unit offering at \$0.70 per unit.

Financial news for RXII dated on 2018-10-01: A Peek Into The Markets: US Stock Futures Up; Dow Futures Rise Over 200 Points

Financial news for RXII dated on 2018-10-01: RXi Pharma Prices ~21.43M Unit Offering At \$0.70/Unit

Financial news for RXII dated on 2018-09-21: Stocks Which Set New 52-Week Low Yesterday, September 20th

Financial news for RXII dated on 2018-09-18: Stocks Which Set New 52-Week Low Yesterday, September 17th

Financial news for RXII dated on 2018-09-18: The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Financial news for RXII dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for RXII dated on 2018-08-15: RXi Pharmaceuticals, Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells

Financial news for RXII dated on 2018-08-14: RXi Pharmaceuticals Q2 EPS \$(0.46) Down From \$(0.11) YoY, Sales \$58K

Financial news for RXII dated on 2018-08-14: The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Financial news for RXII dated on 2018-08-02: RXi Pharma Reports European Patent Office, Japan Patent Office Granted Patents For xd-rxRNA Technology

Financial news for RXII dated on 2018-08-01: RXi Pharmaceuticals Announces Phase 1/2 Trial With RXI-109 Met Primary Endpoint Showing THAT RXI-109 Is Safe And Well Tolerated In The Dose Escalation Study

Financial news for RXII dated on 2018-07-31: Stocks Which Set New 52-Week Low Yesterday, July 30th

Financial news for RXII dated on 2018-07-30: Stocks Which Set New 52-Week Low Friday, July 27

Financial news for RXII dated on 2018-07-26: Stocks Which Set New 52-Week Low Yesterday, July 25th

Financial news for RXII dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for RXII dated on 2018-07-25: Stocks Which Set New 52-Week Lows Yesterday, July 24th:

Financial news for RXII dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for RXII dated on 2018-07-20: Stocks Which Set New 52-Week Low Yesterday

Financial news for RXII dated on 2018-07-20: Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerva To Offer Shares, Intuitive Surgical's Strong Q2

Financial news for RXII dated on 2018-07-12: 44 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-07-10: 30 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-07-09: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for RXII dated on 2018-07-09: Benzinga's Top Upgrades, Downgrades For July 9, 2018

Financial news for RXII dated on 2018-07-09: H.C. Wainwright Initiates Coverage On RXi Pharmaceuticals with Buy Rating, Announces \$3 Price Target

Financial news for RXII dated on 2018-07-06: Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange

Financial news for RXII dated on 2018-06-28: BioAxone BioSciences Wins a \$1.1M Grant From the National Institute of Neurological Disorders and Stroke

Financial news for RXII dated on 2018-05-22: 44 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-05-21: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for RXII dated on 2018-05-18: RXi Pharmaceuticals PR Confirms Earlier Reports, Says Phase 2 Trial With Samcyprone Meets Primary Effectiveness Objectives And Secondary Safety And Tolerability Objectives

Financial news for RXII dated on 2018-05-18: UPDATE: RXi Pharma Doc Shows Conclusions: 'primary objective of the study was met...[related to] secondary objective...resulted in the best outcomes'

Financial news for RXII dated on 2018-05-18: RXi Pharma Shares Spike to Session High, Now Up 14%, As Traders Circulating 'Project Presentation Day' Doc Showing Results For RXI-109 For Treatment To Reduce Formation Of Hypertrophic Dermal Scars

Financial news for RXII dated on 2018-05-18: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Financial news for RXII dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO

Abstracts, Fibrocell, Ispen And More

Financial news for RXII dated on 2018-05-13: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for RXII dated on 2018-05-11: RXi Pharmaceuticals Shares Up 7.4% After Co. Announced Research Collaboration With Iovance For Advancement Of Immuno-Oncology Therapeutics

Financial news for RXII dated on 2018-05-11: Benzinga Pro's 5 Stocks To Watch Today

Financial news for RXII dated on 2018-05-11: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for RXII dated on 2018-05-11: RXi Pharma Announces a Collaboration with Iovance Biotherapeutics to Evaluate Synergies Between sd-rxRNA and Iovance's Autologous Cell Therapy

Financial news for RXII dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for RXII dated on 2018-05-10: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for RXII dated on 2018-05-10: RXi Pharmaceuticals Q1 EPS \$(0.90) Down From \$(0.12) YoY, Sales \$23K

Financial news for RXII dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for RXII dated on 2018-05-08: RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO

Financial news for RXII dated on 2018-05-08: BZ NOTE: RXi Pharma VP Of Research, Karen Bulock, To Present At New York Oncology Investment Conference At 12 p.m. EDT

Financial news for RXII dated on 2018-05-08: Watching RXi Pharma Shares As Traders Circulate May 8-Dated US PTO Doc For Patent No. '702 B2

Financial news for RXII dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for RXII dated on 2018-05-04: Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

Financial news for RXII dated on 2018-04-18: RXi Pharmaceuticals Shares Up 9.9% After Hours As 13G From Intracoastal Capital Shows New 9.2% Stake

Financial news for RXII dated on 2018-04-18: RXi Pharma 13G From Intracoastal Capital Shows New 9.2% Stake

Financial news for RXII dated on 2018-04-16: RXi Pharma Announces Publication in Molecular Therapy on Self-Delivering RNAi Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma

Financial news for RXII dated on 2018-04-11: RXi Pharma 13G Filing From Sabby Mgmt. Shows Reduced Stake From 2.1M Shares At End Of Last Qtr. To ~378K Shares, Or 8.87% Stake

Financial news for RXII dated on 2018-04-09: RXi Pharmaceuticals Announces \$4.9 Million Registered Direct Offering Priced At-the-Market

Financial news for RXII dated on 2018-04-05: 36 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-04-04: Mid-Afternoon Market Update: Dow Turns Positive; RMG Networks Holding Shares Plummet

Financial news for RXII dated on 2018-04-04: Mid-Day Market Update: Cloudera Falls Following Disappointing Outlook; Proteostasis Therapeutics Shares Gain

Financial news for RXII dated on 2018-04-04: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RXII dated on 2018-04-04: Mid-Morning Market Update: Markets Open Lower; Lennar Earnings Top Views

Financial news for RXII dated on 2018-04-04: RXi Pharma Shares Halted On Circuit Breaker, Up 55.9%

Financial news for RXII dated on 2018-04-04: RXi Pharma To Present Updated Clinical, Cosmetic Dermatology Programs At IIDC

Financial news for RXII dated on 2018-04-03: 41 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-03-28: 38 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-03-27: Mid-Afternoon Market Update: NASDAQ Down Over 100 Points; Invitae Shares Fall Following Announcement Of \$50M Common Stock Offering

Financial news for RXII dated on 2018-03-27: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for RXII dated on 2018-03-27: Mid-Day Market Update: Dow Rises Over 100 Points; InspireMD Shares Spike Higher

Financial news for RXII dated on 2018-03-27: Mid-Morning Market Update: Markets Edge Lower; McCormick Profit Tops Estimates

Financial news for RXII dated on 2018-03-26: RXi Pharma Q4 EPS \$(0.84) vs \$(6.02) In Same Qtr. Last Year, Sales \$15K vs No Sales YoY

Financial news for RXII dated on 2018-03-26: UPDATE: RXi Pharma Says Purchase Of MirImmune Resulted In \$1.6M Increase To Acquired In-Process R&D Expense, Corresponding \$1.6M Income Tax Benefit From Reduction Of Valuation Allowance Which Were Not Accounted For Properly

Financial news for RXII dated on 2018-03-26: UPDATE: RXi Pharma Says Previously Reported Results Did Not Include Contemplation Of Deferred Taxes Based On Different Book Basis, Tax Basis For Purchase Of MirImmune

Financial news for RXII dated on 2018-03-26: RXi Pharma 8-K Shows Board, Audit Committee Determined Co.'s Interim Financial Statements For Qtrs. Ended Mar. 31, 2017, Jun. 30, 2017, Sept. 30, 2017 Should No Longer Be Relied Upon

Financial news for RXII dated on 2018-03-26: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for RXII dated on 2018-03-26: Earnings Scheduled For March 26, 2018

Financial news for RXII dated on 2018-03-20: 42 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-03-19: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for RXII dated on 2018-03-19: 48 Biggest Movers From Friday

Financial news for RXII dated on 2018-03-16: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for RXII dated on 2018-03-16: 55 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-03-15: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for RXII dated on 2018-03-15: 42 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-03-14: 45 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-03-13: 46 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-03-12: 44 Biggest Movers From Friday

Financial news for RXII dated on 2018-03-07: Several Low-Float Stocks Seeing Significant Volatility Wed.: Zosano Pharma Shares Up 61% (2M Shares Outstanding), Oragenics Up 47% (5M Shares Outstanding), Innovate Down 7% For Session, Up 15% From Lows (14M Shares), OpGen Down 14% From Highs (5M Shares)

Financial news for RXII dated on 2018-02-08: 19 Biotech Stocks With Clinical Trial Outcomes In February

Financial news for RXII dated on 2018-01-24: RXi Pharma Regains NASDAQ Listing Compliance

Financial news for RXII dated on 2018-01-17: 42 Biggest Movers From Yesterday

Financial news for RXII dated on 2018-01-16: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for RXII dated on 2018-01-16: RXi Pharma Gives a Strategy Update, Plans to Focus on Immuno-Oncology Programs

Financial news for RXII dated on 2018-01-05: RXi Pharmaceuticals Announces 1-for-10 Reverse Stock Split

Financial news for RXII dated on 2017-12-29: 7 Notable Biotechs With Data Expected By Year's End

Financial news for RXII dated on 2017-12-18: 34 Stocks Moving In Monday's Mid-Day Session

Financial news for RXII dated on 2017-12-18: RXi Pharmaceuticals Shares Up 20.97% Premarket; Earlier Co. Announced RXI-109 Met Primary and Secondary Endpoints In Phase 2 Trial

Financial news for RXII dated on 2017-12-18: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for RXII dated on 2017-12-18: RXi Pharmaceuticals Announces 'Positive' Results from Phase 2 Trial with RXI-109 for Dermal Scarring

Financial news for RXII dated on 2017-12-11: RXi Pharma Reports Collaboration With Medigene

Financial news for RXII dated on 2017-11-29: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RXII dated on 2017-11-29: 35 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RXII dated on 2017-11-29: RXi Pharmaceuticals Announces Positive Results with RXI-231 in Consumer Testing Program

Financial news for RXII dated on 2017-11-13: RXi Pharma Announces a Collaboration Agreement with Gustave Roussy

Financial news for RXII dated on 2017-11-08: RXi Pharma Reports Q3 Net Loss \$2.5M vs \$2.2M In Same Qtr. Last Year

Financial news for RXII dated on 2017-09-15: BioAxone in Collaboration with RXi Pharma is Awarded a \$1.8M Grant from the National Institute of Neurological Disorders and Stroke

Financial news for RXII dated on 2017-08-10: RXi Pharma Reports Q2 EPS \$(0.11) vs \$(0.34) In Same Qtr. Last Year

Financial news for RXII dated on 2017-08-09: RXi Pharma Enters Into Stock Purchase Agreement with Lincoln Park Capital to Sell up to \$15M of Shares

Financial news for RXII dated on 2017-08-08: RXi Pharma Selects Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing

Financial news for RXII dated on 2017-05-22: RXi Pharma to Extend Collaboration with PCI Biotech

Financial news for RXII dated on 2017-05-11: RXi Pharmaceuticals Reports Q1 EPS \$(0.27) vs \$(0.34) In Prior Year Quarter

Financial news for RXII dated on 2017-04-26: RXi Pharmaceuticals CEO Geert Cauwenbergh Buys 10,000 Shares @ Avg Price: \$0.65 -Form4

Financial news for RXII dated on 2017-04-13: RXi Pharmaceuticals Granted New Japanese Patent For RXI-109

Financial news for RXII dated on 2017-03-30: RXi Pharma Reports Q4 EPS \$(0.60) vs \$(0.40) in Same Qtr. Last Year

Financial news for RXII dated on 2017-03-30: Earnings Scheduled For March 30, 2017

Financial news for RXII dated on 2017-03-28: RXi Pharmaceuticals Granted Patent in Japan for Clinical Candidate RXI-109

Financial news for RXII dated on 2017-03-10: How The Ultra-Wealthy Are Helping Advance Health And Life Sciences

Financial news for RXII dated on 2017-01-19: RXi Pharmaceuticals Corp: CAUWENBERGH GEERT (Director, President & CEO) Buys 10,000 @ Avg Price: \$0.69 (Form4)

Financial news for RXII dated on 2017-01-12: 13G Filing from Opko Health on RXi Pharma Shows New 5.11% Stake

Financial news for RXII dated on 2016-12-19: Sabby Management Reports 5% Stake In RXi Pharmaceuticals

Financial news for RXII dated on 2016-12-16: BZ NOTE: Opgen Has Previously Been a Rumor Mill Stock; Shares Spiked 300+% in Late Jul. Following Chatter of Business Overlap with Merck; Shares Gave Back All Those Gains And Then Some Since Then

Financial news for RXII dated on 2016-12-16: Mid-Morning Market Update: Markets Open Higher; Adobe Beats Q4 Expectations

Financial news for RXII dated on 2016-12-16: RXi Pharma Prices \$10M Offering

Financial news for RXII dated on 2016-12-13: RXi Pharmaceuticals Provides Year End Update on its Business Development and Clinical Programs

Financial news for RXII dated on 2016-11-23: 18 Biggest Mid-Day Losers For Wednesday

Financial news for RXII dated on 2016-11-22: 15 Biggest Mid-Day Losers For Tuesday

Financial news for RXII dated on 2016-11-22: 18 Stocks Moving In Tuesday's Pre-Market Session

Financial news for RXII dated on 2016-11-10: RXi Pharmaceuticals Reports Q3 EPS \$(0.34) vs. Est. \$(0.34)

Financial news for RXII dated on 2016-10-12: 12 Biggest Mid-Day Losers For Wednesday

Financial news for RXII dated on 2016-10-12: RXi Pharmaceuticals Plans to Conduct Securities Offering

Financial news for RXII dated on 2016-10-12: RXi Pharma to Acquire MirImmune, Terms Not Disclosed

Financial news for RXII dated on 2016-08-11: RXi Pharmaceuticals Reports Q2 EPS \$(0.34) vs. Est. \$(0.36)

Financial news for RXII dated on 2016-06-07: H.C. Wainwright Assumes RXi Pharmaceuticals at Buy, Announces \$3.50 PT

Financial news for RXII dated on 2016-05-12: RXi Pharmaceuticals Reports Q1 EPS \$(0.34) vs. Prior Year Quarter \$(1.32)

Financial news for RXII dated on 2016-05-10: RXi Pharma Announces Exploring Strategic Alternatives

Financial news for RXII dated on 2016-05-03: RXi Pharmaceuticals, Thera Neuropharma Enter into Exclusive License Agreement for RXi's Self-Delivering RNAi Platform Targeting SOD1 to Develop Therapeutics for Neurodegenerative Diseases, Such as ALS

Financial news for RXII dated on 2016-05-02: RXi Pharmaceuticals Secures European Patent for Novel RNAi Platform

Financial news for RXII dated on 2016-04-22: Stocks Hitting 52-Week Lows

Financial news for RXII dated on 2016-04-19: RXi Pharma Announces Allowance for RXI-109 as Lead Clinical Candidate

Financial news for RXII dated on 2016-04-15: RXi Pharma Announces 1-for-10 Reverse Stock Split

Financial news for RXII dated on 2016-03-31: RXi Pharmaceuticals Strengthens IP Portfolio With Patent Issue Notification #9,303,259

Financial news for RXII dated on 2016-03-30: RXi Pharma Reports Q4 EPS \$(0.04) Vs Est \$(0.05)

Financial news for RXII dated on 2016-03-30: Earnings Scheduled For March 30, 2016

Financial news for RXII dated on 2015-12-21: RXi Pharma Announces Start of Phase 2 Trial

Financial news for RXII dated on 2015-11-12: RXi Pharma Reports Inline Q3 EPS \$(0.04)

Financial news for RXII dated on 2015-10-20: RXi Pharmaceuticals Announces Remarkable and Positive Results with its Novel Self-Delivering RNAi Platform: Potent Reduction

of Long Non-coding RNAs Demonstrated in Collaboration with Biogazelle

Financial news for RXII dated on 2015-10-15: RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109

Financial news for RXII dated on 2015-10-05: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO

Financial news for RXII dated on 2015-09-28: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109

Financial news for RXII dated on 2015-08-31: RXi Pharmaceuticals Reports Advancements in its Ophthalmology Clinical Program with RXI-109

Financial news for RXII dated on 2015-06-09: RXi Pharma Announces Two Allowances from USPTO

Financial news for RXII dated on 2015-06-03: RXi Pharmaceuticals Given Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Eye Use

Financial news for RXII dated on 2015-06-02: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology

Financial news for RXII dated on 2015-05-28: RXi Pharma Reports \$10M Offering

Financial news for RXII dated on 2015-05-27: RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

Financial news for RXII dated on 2015-05-27: RXi Pharma Announces Offering of Common Stock, Warrants

Financial news for RXII dated on 2015-04-17: RXi Pharmaceuticals Given Orphan Drug Designation for Samcyprone from the U.S. FDA for Treatment of Malignant Melanoma Stage IIb to IV

Financial news for RXII dated on 2015-04-13: S-1 from RXI Pharma Shows Registration for \$20M Stock and Warrants Offering

Financial news for RXII dated on 2015-03-30: RXi Pharma Corp. Reports Q4 EPS (0.13) vs. Est. \$(0.14), Rev. \$14K vs. Est. \$20K

Financial news for RXII dated on 2015-03-27: RXi Pharmaceuticals, MirImmune Enter Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer

Financial news for RXII dated on 2015-02-05: RXi Pharmaceuticals Announces Closing of Exclusive Global Licensing Agreement to Samcyprone with Hapten Pharmaceuticals

Financial news for RXII dated on 2015-02-03: RXi Pharmaceuticals Granted Patent for Delivery of Double Stranded siRNAs Across Blood-Retina Barrier

Financial news for RXII dated on 2014-12-19: RXI Pharma Announces Expansion of Clinical Pipeline with Exclusive License for Second Phase 2 Clinical Compound

Financial news for RXII dated on 2014-10-07: RXi Pharmaceuticals To Present New Data In Its First Phase 2a Clinical Trial With RXI-109

Financial news for RXII dated on 2014-09-16: RXI Pharmaceuticals CEO Cauwenbergh Buys 5,000 Shares @\$2.08/Share -Form 4

Financial news for RXII dated on 2014-09-15: RXI Pharmaceuticals CEO Cauwenbergh Buys 10,000 Shares @\$2.18/Share -Form 4

Financial news for RXII dated on 2014-09-11: RXi Pharma Reports RXI-109 Shown to Be Well Tolerated in Results to Date, Requested Pre-IND Meeting

Financial news for RXII dated on 2014-08-14: RXI Pharma Reports Q2 EPS of \$(0.23) Which May Not Compare \$(0.25) Est; Revenue of \$3.20M Which May Not Compare \$50.0K Est

Financial news for RXII dated on 2014-07-30: RXi Announces Initiation of Phase 2a Study For RXI-109

Financial news for RXII dated on 2014-07-07: RXi Pharmaceuticals Appoints Peter Campochiaro M.D. To Its Scientific Advisory Board

Financial news for RXII dated on 2014-05-14: RXI Pharma Reports Q1 EPS of \$(0.32) vs \$(0.31) Est

Financial news for RXII dated on 2014-05-05: Wainwright Initiates Coverage on RXI

Pharmaceuticals at Buy, Announces \$9.00 PT

Financial news for RXII dated on 2014-05-02: RXi Pharmaceuticals Announces Positive Results with RXI-109 Study

Financial news for RXII dated on 2014-04-28: RXi Pharmaceuticals to Present at ARVO 2014 Annual Meeting

Financial news for RXII dated on 2014-04-23: Filing from RXI Pharma Shows Prospectus for \$20.4M in Shares

Financial news for RXII dated on 2014-04-22: RXi Pharma Announces Financing Facility with Lincoln Park Capital for Up to \$20M

Financial news for RXII dated on 2014-04-01: RXI Pharma Files \$100M Mixed Securities Shelf

Financial news for RXII dated on 2013-11-13: RXi Pharmaceuticals Initiates First Phase 2 Study with RXI-109

Financial news for RXII dated on 2013-07-12: RXi Pharmaceuticals Reports Positive Phase 1 Data in Multi-Dose Study

Financial news for RXII dated on 2013-03-22: 13D from Opko Health Showing 20.9% Stake in RXi Pharma

Financial news for RXII dated on 2012-11-15: RXi Pharmaceuticals Announces Phase 1 Study Results for RXI-109

Financial news for RXII dated on 2012-09-24: RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program

Financial news for RXII dated on 2012-05-10: Galena Biopharma Notified That RXi Pharmaceuticals' Common Stock to Commence Trading Under Ticker Symbol "RXII"

Financial news for RXII dated on 2011-09-26: RXi Pharmaceuticals To Split Into Publicly Traded Companies

Financial news for RXII dated on 2011-09-26: Financial Breakfast: Morning News Summary for September 26, 2011

Financial news for RXII dated on 2011-09-26: RXi Pharmaceutical to Separate Into Two Publicly Traded Companies

Financial news for RXII dated on 2011-09-23: Pharma/Biotech Stocks Reporting on Breast Cancer Treatments

Financial news for RXII dated on 2011-09-21: RXi Pharmaceuticals Licenses Novel, Targeted Cancer Vaccine for Gynecological Cancers

Financial news for RXII dated on 2011-09-13: Biotech/Pharma Stocks to Watch: BioSante, RXi, Dendreon, Catalyst Pharmaceutical Partners

Financial news for RXII dated on 2011-09-12: RXi Pharmaceuticals Provides Positive NeuVax Phase 3 Clinical Trial Update

Financial news for RXII dated on 2011-07-13: RXi Pharmaceuticals Strengthens NeuVax Patent Portfolio

Financial news for RXII dated on 2011-07-12: RXi Pharmaceuticals Spiking Higher on Heavy Volume

Financial news for RXII dated on 2011-06-13: RXi Pharmaceuticals Files to Sell 4.97M Shares

Financial news for RXII dated on 2011-06-08: RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results for Combination of NeuVaxTM and Trastuzumab Breast Cancer at ASCO

Financial news for RXII dated on 2011-06-06: Morning Market Movers

Financial news for RXII dated on 2011-06-06: RXi Pharmaceuticals Announces Positive NeuVaxTM (E75) Phase 2 Efficacy Results After 36 Months of Follow-Up

Financial news for RXII dated on 2011-05-19: RXi Pharmaceuticals Presents Updated NeuVax Data At ASCO

Financial news for RXII dated on 2011-04-26: RXi Pharmaceuticals Awarded \$580K in NIH Grants to Advance RNAi Therapeutics

Financial news for RXII dated on 2011-04-15: RXi Pharmaceuticals Prices \$12 Million Public Offering of Common Stock and Warrants, 11.95 Units Priced At \$1.00 Each (RXII)

Financial news for RXII dated on 2011-04-14: RXi Pharmaceuticals Announces Public Offering of Common Stock and Warrants

Financial news for RXII dated on 2011-04-14: A Peek Into The Market Before The Trading Starts

Financial news for RXII dated on 2011-04-14: RXi Pharmaceuticals Completes Apthera Acquisition, Apthera Stockholders Will Initially Receive Approximately 4.8M Shares (RXII)

Financial news for RXII dated on 2011-03-01: RXi Pharmaceuticals Prices \$8.1 Million Public Offering

Financial news for RXII dated on 2011-02-28: RXi Pharmaceuticals Announces Offering of Common Stock and Warrants

Financial news for RXII dated on 2011-01-12: CytRx Raises \$7 Million from Sale

Financial news for RXII dated on 2010-11-15: RXi Pharmaceuticals Reports Third Quarter EPS of \$(0.23)

Financial news for RXII dated on 2010-07-13: RXi Pharmaceuticals Awarded NIH Grant

Financial news for RXII dated on 2010-01-14: Wednesday's Hot Stocks: Finding A Rose Among Many Thorns

Financial news for RXII dated on 2010-01-14: Benzinga's News Roundup (SEED, WSM, FPL, SNSS, ETRM, AIR, RXII)